BLOOD PRESSURE REDUCTION WITH THE NOVEL DUAL-ACTING ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR LCZ696: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR STUDY